Literature DB >> 16278037

Vaccines against typhoid fever.

Carlos A Guzman1, Stefan Borsutzky, Monika Griot-Wenk, Ian C Metcalfe, Jon Pearman, Andre Collioud, Didier Favre, Guido Dietrich.   

Abstract

Because of high infectivity and significant disease burden, typhoid fever constitutes a major global health problem. Implementation of adequate food handling practices and establishment of safe water supplies are the cornerstone for the development of an effective prevention program. However, vaccination against typhoid fever remains an essential tool for the effective management of this disease. Currently, there are two well tolerated and effective licensed vaccines. One is based on defined subunit virulence (Vi) polysaccharide antigen and can be administered either intramuscularly or subcutaneously and the other is based on the use of live attenuated bacteria for oral administration. The advantages and disadvantages of the various approaches taken in the development of a vaccine against typhoid fever are discussed, along with the potential for future vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278037     DOI: 10.1016/j.vaccine.2005.07.111

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  57 in total

1.  Enteric fever imported to the Czech Republic: epidemiology, clinical characteristics and antimicrobial susceptibility.

Authors:  Milan Trojánek; Daniela Dědičová; Helena Žemličková; Vladislav Jakubů; Eliška Malíková; Marie Reisingerová; Alice Gabrielová; Costas C Papagiannitsis; Jaroslav Hrabák; Blanka Horová; Pavla Urbášková; Vilma Marešová; František Stejskal
Journal:  Folia Microbiol (Praha)       Date:  2014-11-14       Impact factor: 2.099

Review 2.  Salmonella: from pathogenesis to therapeutics.

Authors:  Erin C Boyle; Jennifer L Bishop; Guntram A Grassl; B Brett Finlay
Journal:  J Bacteriol       Date:  2006-12-22       Impact factor: 3.490

3.  Dual Immunization with SseB/Flagellin Provides Enhanced Protection against Salmonella Infection Mediated by Circulating Memory Cells.

Authors:  Seung-Joo Lee; Joseph Benoun; Brian S Sheridan; Zachary Fogassy; Oanh Pham; Quynh-Mai Pham; Lynn Puddington; Stephen J McSorley
Journal:  J Immunol       Date:  2017-07-14       Impact factor: 5.422

4.  Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.

Authors:  Sonia Domingos-Pereira; Valérie Cesson; Mathieu F Chevalier; Laurent Derré; Patrice Jichlinski; Denise Nardelli-Haefliger
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

5.  Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Authors:  Leslie W J Baillie; Ana L Rodriguez; Stephen Moore; Helen S Atkins; Chiguang Feng; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2008-09-19       Impact factor: 3.641

6.  Generation of Salmonella-specific Th1 cells requires sustained antigen stimulation.

Authors:  Amanda J Griffin; Stephen J McSorley
Journal:  Vaccine       Date:  2011-02-20       Impact factor: 3.641

7.  Update on imminent vaccines: report of the APPA VU 2010: II.

Authors:  Sunil Karande
Journal:  Indian J Pediatr       Date:  2011-03-05       Impact factor: 1.967

Review 8.  Salmonella infection: Interplay between the bacteria and host immune system.

Authors:  Jonathan R Kurtz; J Alan Goggins; James B McLachlan
Journal:  Immunol Lett       Date:  2017-07-15       Impact factor: 3.685

9.  The expanding spectrum of disease due to salmonella: an international perspective.

Authors:  Laila Woc-Colburn; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

10.  Salmonella enterica serovar typhimurium strains with regulated delayed attenuation in vivo.

Authors:  Roy Curtiss; Soo-Young Wanda; Bronwyn M Gunn; Xin Zhang; Steven A Tinge; Vidya Ananthnarayan; Hua Mo; Shifeng Wang; Wei Kong
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.